Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Contraceptive Drugs and Devices Market – Segmented by Contraceptive Method, by Mode of Delivery, by Type of Device, by Gender and Geography – Growth, Trends and Forecasts (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| Unknown | Published: 25-06-2019 |
- Healthcare
- Mordor Intelligence
- pages
- Published: 25-06-2019
The major factors propelling the growth of the contraceptive drugs and devices market includes the increasing incidence of the STD, an increasing rate of unintended pregnancies, and the rise in government initiatives.
Scope of the Report
As per the scope of the report, contraceptive drugs and devices are the drugs and devices used for birth control. Contraception is more commonly known as fertility and birth control is described as the method used to avoid pregnancy. These devices and drugs function by changing the mechanism of ovulation or by acting as a physical barrier between the sperm and ovum. The proper use of contraceptives, such as female and male condoms also prevents the spread of sexually transmitted diseases.
Key Market Trends
Oral Contraceptives is Estimated to have Largest Share in the Segmentation by Drugs over the Forecast Period
Oral contraceptive pills are seen as the easiest method of contraception in the industry. They act by prohibiting implantation within the uterus if taken within 2-3 days of having unsafe sexual contact. The simplicity of their usage makes them an ideal contraceptive in the market. These are easily marketed across large regions by global companies and thus easily consumed by a large section of the population, globally. These factors are expected to contribute to the growth of the market over the forecast period. The other forms of contraceptive drugs, such as topical and injectable contraceptives have also witnessed a strong market demand.
North America has been Reported with the Largest Share and Consistent Growth over the Forecast Period.
North America is expected to register a high growth, owing to the presence of sophisticated healthcare infrastructure, the high adoption rate of contraceptive drugs, and the rising number of government initiatives that help in increasing the overall market. A large section of the women population represents the reproductive age in the United States as well as Canada. With that, a significant size of the population is at risk of unintended pregnancy, as their partners do not use a contraceptive method, correctly and consistently. The awareness regarding these products is also high with considerable support being provided by several hospitals to control the patients affected by its misuse. Moreover, the distribution channel of several companies is well established across the United States and Canada, which overall drives the market and contributes to the largest share, over the forecast period.
Competitive Landscape
Over the forecast period, most of the domestic and international players are found focusing on the emerging market and these countries are growing rapidly in the contraceptive drugs and devices market.
Table of Contents
1. INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of the STDs
4.2.2 Increasing Rate of Unintended Pregnancies
4.2.3 Rise in Government Initiatives
4.3 Market Restraints
4.3.1 High Cost of Devices and Treatment
4.3.2 Side Effects Associated with the Use of Contraceptive Drugs and Devices
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Products
5.1.1 By Drugs
5.1.1.1 Oral Contraceptives
5.1.1.2 Topical Contraceptives
5.1.1.3 Contraceptive Injectable
5.1.2 By Device
5.1.2.1 Condoms
5.1.2.2 Diaphragms
5.1.2.3 Cervical Caps
5.1.2.4 Sponges
5.1.2.5 Vaginal Rings
5.1.2.6 IUD
5.1.2.7 Other Devices
5.2 By Gender
5.2.1 Male
5.2.2 Female
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Pfizer Inc.
6.1.3 Merck & Co. Inc.
6.1.4 Teva Pharmaceuticals Ltd
6.1.5 Agile Therapeutics
6.1.6 Allergan PLC
6.1.7 Ani Pharmaceuticals Inc.
6.1.8 Church & Dwight Co. Inc.
6.1.9 Fuji Latex Co. Ltd
6.1.10 Johnson & Johnson Ltd
*List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
MARKET SEGMENTATION
By Products
By Drugs
Oral Contraceptives
Topical Contraceptives
Contraceptive Injectable
By Device
Condoms
Diaphragms
Cervical Caps
Sponges
Vaginal Rings
IUD
Other Devices
By Gender
Male
Female
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Electronic Medical Records Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| Unknown | Published: 25-06-2019 |
- Healthcare
- Mordor Intelligence
- pages
- Published: 25-06-2019
Market Overview
Electronic medical record (EMR) systems are becoming increasingly popular, as the healthcare industry is moving toward digitization. A lot of government initiatives, such as encouraging physicians to adopt electronic health records, investing in training the healthcare information technology workers, and establishing regional extension centers to provide technical and other advices are triggering the EMR market’s growth.
Moreover, factors, like rising need for integrated healthcare system, big data trends in healthcare industry, and technological advancements in the field of data storage are driving the growth of the EMR market. On the other hand, factors, like data privacy concerns, high initial investment, shortage of proper trained staff, and inter-operability issues are the primary restraints in the growth of the electronic medical records market.
Scope of the Report
Electronic health record (EHR) is a computerized version of paper record that stores information securely and is visible to other authorized users/practitioners. It is an electronic version of patient medical history, which is maintained and includes all data related to patients care under particular doctor, including demographics, progress notes, problems, medication and vital signs, past medical history, immunizations, laboratory data, and radiology reports.
Key Market Trends
The Cloud Based Segment Holds the Largest Share in the Electronic Medical Records Market
Based on mode of delivery, the electronic health record market is further segmented into cloud based and on-premise. Among these, cloud based holds the largest share in the electronic medical records market. This is attributed due to the rise in number of benefits, such as low licensing and start-up cost, low cost of maintenance and infrastructure requirements, and wider accessibility. In addition, a cloud-based EHR system provides enhanced productivity and faster and smoother implementation.
Based on end user, the electronic health record market is classified into hospital-based EMR and physician-based EMR. Hospital-based EMR held the largest share as an end-user segment in this market. The growth in this end-user segment is attributed to the increasing number of hospitals, globally, and several advantages associated with using EHR and easy availability of patient-centric data.
North America Dominates the Electronic Medical Records Market, Globally, During the Forecast Period
The healthcare IT market in the United States is one of the most established markets, compared to other geographical regions. Additionally, most hospitals and clinics in the region have widely implemented EHR solutions, due to stringent regulatory norms. Canada and the United States are the leading countries in this region that have implemented EHR systems. Asia-Pacific is anticipated to grow during the forecast period. Emerging countries, including India and China, have been experiencing strong economic growth. Increasing demand for the healthcare IT services and increasing expenditure by the governments in the emerging countries are expected to propel the EHR market in the Asia-Pacific region. In addition, China is the home for producing low-cost electronic components, which is anticipated to attract more investors.
Globally, governments have advised hospitals and clinics to change conventional health records into an electronic format for better storage of patient data. For instance, the U.S. government is taking initiatives to increase the use of EHR. The Health Information Technology for Economic and Clinical Health (HITECH) Act was authorized as a component of the American Recovery and Reinvestment Act (ARRA). This act was passed in 2009 to advance the utilization of EHR systems, with a specific end goal for modernizing and improving the healthcare system.
Competitive Landscape
Major market players in the global electronic health records market are actively participating in the development of new platform for the patient records. For instance, in May 2018, Cerner Corporation announced the agreement with Cerner Government Services Inc. for transitioning service members and their care providers’ access to a single electronic health record system. In April 2018, eClinicalWorks announced the partnership with Waverly Health Center (WHC), the partnership aimed to transform the WHC, Paragon Inpatient EHR system to the eClinicalWorks cloud-centric Acute Care EHR and Revenue Cycle Management platform.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
Table of Contents
1. INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Initiatives by the Governments
4.2.2 Technological Advancements
4.2.3 Low Maintenance and Wider Accessibility
4.3 Market Restraints
4.3.1 Data Privacy Concerns
4.3.2 High Initial Investment
4.3.3 Shortage of Proper Trained Staff
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Component
5.1.1 Hardware
5.1.2 Software
5.1.3 Services and Consulting
5.2 End User
5.2.1 Hospital-based EMR
5.2.2 Physician-based EMR
5.3 Functionality
5.3.1 Basic Systems
5.3.2 Fully Functional Systems
5.4 Application
5.4.1 Specialty Based
5.4.1.1 Cardiology
5.4.1.2 Neurology
5.4.1.3 Radiology
5.4.1.4 Oncology
5.4.1.5 Other Applications
5.4.2 General Applications
5.5 Type
5.5.1 Traditional EMRs
5.5.2 Speech enabled EMRs
5.5.3 Interoperable EMRs
5.5.4 Other Types
5.6 Mode of Delivery
5.6.1 Cloud Based
5.6.2 On-premise Model
5.7 Geography
5.7.1 North America
5.7.1.1 US
5.7.1.2 Canada
5.7.1.3 Mexico
5.7.2 Europe
5.7.2.1 Germany
5.7.2.2 UK
5.7.2.3 France
5.7.2.4 Italy
5.7.2.5 Spain
5.7.2.6 Rest of Europe
5.7.3 Asia-Pacific
5.7.3.1 China
5.7.3.2 Japan
5.7.3.3 India
5.7.3.4 Australia
5.7.3.5 South Korea
5.7.3.6 Rest of Asia-Pacific
5.7.4 Middle East & Africa
5.7.4.1 GCC
5.7.4.2 South Africa
5.7.4.3 Rest of Middle East & Africa
5.7.5 South America
5.7.5.1 Brazil
5.7.5.2 Argentina
5.7.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 eClinicalWorks
6.1.2 McKesson
6.1.3 Cerner Corporation
6.1.4 Allscripts
6.1.5 Meditech
6.1.6 GE Healthcare
6.1.7 Epic
6.1.8 Next Gen Healthcare
6.1.9 Greenway Health
*List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Component
Hardware
Software
Services and Consulting
End User
Hospital-based EMR
Physician-based EMR
Functionality
Basic Systems
Fully Functional Systems
Application
Specialty Based
Cardiology
Neurology
Radiology
Oncology
Other Applications
General Applications
Type
Traditional EMRs
Speech enabled EMRs
Interoperable EMRs
Other Types
Mode of Delivery
Cloud Based
On-premise Model
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Asia-Pacific Remote Patient Monitoring Systems Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 86 pages | Published: 17-06-2019 |
- Healthcare
- Mordor Intelligence
- 86 pages
- Published: 17-06-2019
Market Overview
The Asia-Pacific remote monitoring systems market is projected to register a CAGR of almost 12.9%, over the forecast period. Certain factors that are propelling the growth of the market are the rising incidences of chronic diseases due to lifestyle changes, increase in the aging population, need to contain healthcare expenditure, demand for home-based monitoring devices, and ease of use and portability devices to promote the growth.
The adoption of various home-based monitoring devices has helped in the growth of the healthcare industry, drastically. The switch toward home care and preventive care has led to the higher acceptance of remote patient monitoring devices. With the help of these devices, the patients can keep a track of their well-being and the doctors can offer accurate diagnosis. These devices are also helping patients recover better after surgeries and during treatments. However, a paradigm shift toward home-based monitoring is increasing, which is driving the remote patient monitoring systems market.
Scope of the Report
Remote patient monitoring is a technology, which helps in the monitoring of patients outside of a usual hospital or clinical facilities. This helps in increasing the access to care and decreasing the healthcare delivery costs.
Key Market Trends
Heart Monitors are Expected to Witness the Highest CAGR over the Forecast Period
With the advancements in technology and rapid adoption of digital healthcare in developing countries, there is a huge demand for remote monitoring devices. Among these devices or systems, heart monitors have a huge demand across developing countries, such as India and China.
The rising prevalence of heart diseases in the Asia-Pacific region is one of the major factors contributing to the huge demand for heart monitors. According to the World Health Organization, around 26.2% of deaths in the Asia-Pacific region are associated with cardiovascular diseases. Furthermore, the prevalence of hypertension in the region is approximately 16-18%.
Owing to the rising number of people suffering from medical issues, such as hypertension, blood pressure fluctuations, heart failure, etc., the demand for remote monitoring devices is increasing.
Japan Dominates the Market and is Expected to Follow the Same Trend over Forecast Period
Geographically, the Asian market has been segmented under various regions, namely, China, Japan, India, Australia & New Zealand, and South Korea. Currently, Japan dominates the Asia-Pacific patient monitoring system market, which is followed by China, India, and South Korea. The market is majorly driven by factors, like the increasing number of chronic disease in Asia-Pacific, as two in three deaths were caused due to chronic disease.
Competitive Landscape
The Asia-Pacific remote patient monitoring market is moderately competitive and inclusive of the major players, such as GE Healthcare, Abbott Laboratories, Baxter, Boston Scientific, and Omron Healthcare.
Due to the growing digital healthcare market, small players are also focusing on entering the market, and are anticipated to grab a substantial market share in the coming future.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Chronic Diseases due to Lifestyle Changes
4.2.2 Increase in Ageing Population
4.2.3 Need to Contain Healthcare Expenditure
4.2.4 Demand for Home-based Monitoring Devices
4.2.5 Ease of Use and Portability Devices to Promote the Growth
4.3 Market Restraints
4.3.1 Resistance from Healthcare Industry Professionals toward the Adoption of Patient Monitoring Systems
4.3.2 Stringent Regulatory Framework
4.3.3 Lack of Trained Staff and Physicians
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Heart Monitors
5.1.2 Breath Monitors
5.1.3 Hematology Monitors
5.1.4 Multi-parameter monitors
5.1.5 Other Types
5.2 By Application
5.2.1 Cancer Treatment
5.2.2 Cardiovascular Disease
5.2.3 Diabetes Treatment
5.2.4 Sleep Disorder
5.2.5 Weight Management and Fitness Monitoring
5.2.6 Other Applications
5.3 By End-users
5.3.1 Home Healthcare
5.3.2 Ambulatory Care Centers
5.3.3 Hospitals
5.3.4 Other End Users
5.4 Geography
5.4.1 Asia-Pacific
5.4.1.1 China
5.4.1.2 Japan
5.4.1.3 India
5.4.1.4 Australia & New Zealand
5.4.1.5 South Korea
5.4.1.6 Rest of Asia-Pacific
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Omron Healthcare
6.1.3 AMD South America Telemedicine
6.1.4 Baxter
6.1.5 Bosch Medical
6.1.6 Boston Scientific
6.1.7 Cardiocom
6.1.8 Covidien
6.1.9 GE Healthcare
6.1.10 Nihon Kohden
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Heart Monitors
Breath Monitors
Hematology Monitors
Multi-parameter monitors
Other Types
By Application
Cancer Treatment
Cardiovascular Disease
Diabetes Treatment
Sleep Disorder
Weight Management and Fitness Monitoring
Other Applications
By End-users
Home Healthcare
Ambulatory Care Centers
Hospitals
Other End Users
Geography
Asia-Pacific
China
Japan
India
Australia & New Zealand
South Korea
Rest of Asia-Pacific
Asia-Pacific Wearable Medical Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 65 pages | Published: 17-06-2019 |
- Healthcare
- Mordor Intelligence
- 65 pages
- Published: 17-06-2019
Market Overview
– The propelling factors for the growth of the Asia-Pacific (APAC) wearable medical devices market include the increasing technological advancements and innovations, increasing per-capita income in developing countries, and ease-of-use and interpretation of medical devices.
– The APAC wearable medical devices market is expected to witness prolific growth, owing to rapid technological advancements and innovations. The introduction of new wearable devices, such as smart lenses, wireless ECG devices, wireless heart-rate monitors, and blood glucose monitors, have created high awareness among tech-savvy consumers. With further improvements in device design, user interface, cybersecurity, and battery capacity, the usage of wearable medical devices is expected to rise over the forecast period.
– In addition, the developing and emerging regions are supplied with low cost, or completely knocked down versions of the international products to improve market penetration. However, some manufacturers continue to use a uniform product and pricing strategy across the world, where prices are moderated relatively by currency fluctuations and local assembling capacity. Thus, the high price of the products is further impacting the growth of the market.
– In the Asia-Pacific region, a large pool of population has lifestyle diseases, such as diabetes and obesity, which has increased the risk of cancer. This has raised the concerns levels in the societies to early diagnose the diseases, which increases the demand for wearable devices. Furthermore, the increase in cases of chronic conditions, such as obesity, heart problems, breathing problems, and many more such diseases, helps to drive the Asia-Pacific market.
Scope of the Report
As per the scope of the report, wearable medical devices are capable of diagnosing or monitoring medical conditions, combined with digital health information, typically worn over the body. The demand for wearable medical devices and remote patient monitoring is continuously increasing in the global market. Wearable devices are easy to use, cordless, and can provide information about various factors, such as heart rate, blood pressure, weight, sleeping habits, and other factors.
Key Market Trends
Sports and Fitness is Estimated to have the Largest Share in the Asia-Pacific Wearable Medical Devices Market
Sports and fitness devices are the most popular and widely known healthcare wearables, which are used to keep track of vital parameters. The athletes use wearable devices, which measure their heart rate, blood pressure, etc. People, nowadays, have become health conscious and started using wearable medical devices to keep a check on their vital parameters, like pulse rate, blood pressure, etc. Thus, the rise in awareness regarding fitness and preventive care increased the demand for wearable medical devices.
Competitive Landscape
The key growth strategies adopted by key players include strategic acquisitions, collaborations, and partnerships that may help them expand their geographical presence and strengthen their business position.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Technological Advancements and Innovations
4.2.2 Increasing Per-capita Income in Developing Countries
4.2.3 Ease-of-use and Interpretation of Medical Devices
4.3 Market Restraints
4.3.1 High Cost of Wearable Devices
4.3.2 Unfavorable Reimbursement Issues
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Wearable Vital Sign Monitor
5.1.1.1 Wearable Heart Rate Monitor
5.1.1.2 Wearable Activity Monitor
5.1.1.3 Wearable Electrocardiograph
5.1.1.4 Wearable Sleep Monitor
5.1.2 Wearable Fetal Monitor and Obstetric Device
5.1.3 Neuro-monitoring Device
5.1.4 Pain Management Wearable Medical Device
5.1.5 Glucose/Insulin Monitoring Wearable Device
5.1.6 Respiratory Therapy Wearable Device
5.2 By Application
5.2.1 Sports and Fitness
5.2.2 Remote Patient Monitoring
5.2.3 Home Healthcare
5.3 By Device Type
5.3.1 Watch
5.3.2 Wristband
5.3.3 Clothing
5.3.4 Ear Wear
5.3.5 Other Device Types
5.4 Geography
5.4.1 Asia-Pacific
5.4.1.1 China
5.4.1.2 Japan
5.4.1.3 India
5.4.1.4 Australia
5.4.1.5 South Korea
5.4.1.6 Rest of Asia-Pacific
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Garmin Ltd
6.1.2 Apple Inc.
6.1.3 Fitbit Inc.
6.1.4 Lifesense
6.1.5 Sotera Wireless
6.1.6 LifeWatch AG (Biotelemetry)
6.1.7 Philips Electronics
6.1.8 Samsung
6.1.9 Vital connect
6.1.10 Abbott Laboratories
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Wearable Vital Sign Monitor
Wearable Heart Rate Monitor
Wearable Activity Monitor
Wearable Electrocardiograph
Wearable Sleep Monitor
Wearable Fetal Monitor and Obstetric Device
Neuro-monitoring Device
Pain Management Wearable Medical Device
Glucose/Insulin Monitoring Wearable Device
Respiratory Therapy Wearable Device
By Application
Sports and Fitness
Remote Patient Monitoring
Home Healthcare
By Device Type
Watch
Wristband
Clothing
Ear Wear
Other Device Types
Geography
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Diabetes Care Devices Market – Growth, Trends, and Forecast (2012 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 17-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 17-06-2019
Market Overview
The global diabetes care devices market is expected to register a CAGR of about 6.8% during the forecast period (2019 – 2023).
Asia-Pacific is anticipated to dominate the market during the forecast period, owing to rising prevalence of obesity in the region.
There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps.
Technological innovations and advances give much convenience in measuring the blood glucose levels. One such advancement in monitoring the blood glucose levels is established with continuous glucose monitoring devices.
Scope of the Report
The global diabetes care devices market is segmented by management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood glucose (hospital and personal use) and continuous glucose monitoring), and geography.
Key Market Trends
Rising Prevalence of Diabetes
As per a WHO report, the global prevalence of diabetes among adults of over 18 years accelerated from about 4.7%, in 1980, to over 8.5%, in 2014.
Diabetes prevalence has been rising rapidly in the middle- and low-income countries. In 2015, about 1.6 million deaths were directly associated with diabetes, which was around 2.2 million in 2012.
Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO projects that diabetes is likely to be the seventh-leading cause of death by 2030.
The growing prevalence of diabetes is the major driver for the global diabetes care devices market. Additionally, rising awareness regarding diabetes care, growing prevalence of obesity, and technological advancements are further driving the market for diabetes care devices.
North America to Dominate the Monitoring Devices Segment
The factors attributing to the North American market growth is the rising prevalence of diabetes, caused mainly due to urbanization and sedentary lifestyles.
Asia-Pacific is anticipated to grow tremendously during the forecast period, owing to factors, such as a high prevalence of diabetes, growing obese population, and government initiatives of raising awareness regarding diabetic care.
Competitive Landscape
There have been constant innovations driven by manufacturers to compete and struggle in the market. The major players, such as Abbott and Medtronic, resort to inorganic market strategies, such as mergers and acquisitions, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. Examples of few strategic outcomes include:
In March 2018, Medtronic PLC received the US Food and Drug Administration (FDA) approval for Guardian(TM) Connect continuous glucose monitoring (CGM) system, for diabetics aged between aged between 14-75 years.
In January 2018, Abbott announced that the FreeStyleLibre System, the company’s revolutionary new continuous glucose monitoring (CGM) system, was available to Medicare patients in the United States.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Monitoring Devices
5.1.1 Self-Monitoring Blood Glucose Devices
5.1.1.1 By Component (Value and Volume, 2012 – 2024)
5.1.1.1.1 Glucometer Devices
5.1.1.1.2 Test Strips
5.1.1.1.3 Lancets
5.1.1.2 By End User
5.1.1.2.1 Hospital (Value and Volume, 2012 – 2024)
5.1.1.2.1.1 Glucometer Devices
5.1.1.2.1.2 Test Strips
5.1.1.2.1.3 Lancets
5.1.1.2.2 Personal (Value and Volume, 2012 – 2024)
5.1.1.2.2.1 Glucometer Devices
5.1.1.2.2.2 Test Strips
5.1.1.2.2.3 Lancets
5.1.2 Continuous Blood Glucose Monitoring
5.1.2.1 By Component (Value and Volume, 2012 – 2024)
5.1.2.1.1 Sensors
5.1.2.1.2 Receivers
5.2 Management Devices
5.2.1 Insulin Pump
5.2.1.1 Insulin Pump Device
5.2.1.2 Insulin Pump Reservoir
5.2.1.3 Infusion Set
5.2.2 Insulin Syringes
5.2.3 Insulin Cartridges
5.2.4 Disposable Pens
5.2.5 Jet Injectors
5.3 Geography
5.3.1 North America
5.3.1.1 United States (Value and Volume, 2012 – 2024)
5.3.1.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.1.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.1.2 Canada (Value and Volume, 2012 – 2024)
5.3.1.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.1.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.1.3 Rest of North America (Value and Volume, 2012 – 2024)
5.3.1.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.1.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2 Europe
5.3.2.1 France (Value and Volume, 2012 – 2024)
5.3.2.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.2 Germany (Value and Volume, 2012 – 2024)
5.3.2.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.3 Italy (Value and Volume, 2012 – 2024)
5.3.2.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.4 Spain (Value and Volume, 2012 – 2024)
5.3.2.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.5 United Kingdom (Value and Volume, 2012 – 2024)
5.3.2.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.6 Russia (Value and Volume, 2012 – 2024)
5.3.2.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.2.7 Rest of Europe (Value and Volume, 2012 – 2024)
5.3.2.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.2.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.3 Latin America
5.3.3.1 Mexico (Value and Volume, 2012 – 2024)
5.3.3.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.3.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.3.2 Brazil (Value and Volume, 2012 – 2024)
5.3.3.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.3.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.3.3 Rest of Latin America (Value and Volume, 2012 – 2024)
5.3.3.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.3.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4 Asia-Pacific
5.3.4.1 Japan (Value and Volume, 2012 – 2024)
5.3.4.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.2 South Korea (Value and Volume, 2012 – 2024)
5.3.4.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.3 China (Value and Volume, 2012 – 2024)
5.3.4.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.4 India (Value and Volume, 2012 – 2024)
5.3.4.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.5 Australia (Value and Volume, 2012 – 2024)
5.3.4.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.6 Vietnam (Value and Volume, 2012 – 2024)
5.3.4.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.7 Malaysia (Value and Volume, 2012 – 2024)
5.3.4.7.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.7.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.7.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.8 Indonesia (Value and Volume, 2012 – 2024)
5.3.4.8.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.8.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.8.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.9 Philippines (Value and Volume, 2012 – 2024)
5.3.4.9.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.9.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.9.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.10 Thailand (Value and Volume, 2012 – 2024)
5.3.4.10.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.10.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.10.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 – 2024)
5.3.4.11.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.11.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.4.11.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5 Middle East & Africa
5.3.5.1 Saudi Arabia (Value and Volume, 2012 – 2024)
5.3.5.1.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.1.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.1.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.2 Iran (Value and Volume, 2012 – 2024)
5.3.5.2.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.2.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.2.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.3 Egypt (Value and Volume, 2012 – 2024)
5.3.5.3.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.3.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.3.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.4 Oman (Value and Volume, 2012 – 2024)
5.3.5.4.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.4.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.4.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.5 South Africa (Value and Volume, 2012 – 2024)
5.3.5.5.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.5.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.5.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
5.3.5.6 Rest of Middle & Africa (Value and Volume, 2012 – 2024)
5.3.5.6.1 By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.6.2 By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
5.3.5.6.3 By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Dexcom
7.1.5 Medtronic
7.1.6 Arkray
7.1.7 Ascensia Diabetes Care
7.1.8 Agamatrix Inc.
7.1.9 Bionime Corporation
7.1.10 Acon
7.1.11 Medisana
7.1.12 Trivida
7.1.13 Rossmax
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Johnson & Johnson
7.2.3 Abbott Diabetes Care
7.2.4 Dexcom
7.2.5 Medtronic
7.2.6 Novo Nordisk
7.2.7 Eli Lilly
7.2.8 Sanofi
7.2.9 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Monitoring Devices
Self-Monitoring Blood Glucose Devices
By Component (Value and Volume, 2012 – 2024)
Glucometer Devices
Test Strips
Lancets
By End User
Hospital (Value and Volume, 2012 – 2024)
Glucometer Devices
Test Strips
Lancets
Personal (Value and Volume, 2012 – 2024)
Glucometer Devices
Test Strips
Lancets
Continuous Blood Glucose Monitoring
By Component (Value and Volume, 2012 – 2024)
Sensors
Receivers
Management Devices
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Insulin Cartridges
Disposable Pens
Jet Injectors
Geography
North America
United States (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Canada (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of North America (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Europe
France (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Germany (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Italy (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Spain (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
United Kingdom (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Russia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Europe (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Latin America
Mexico (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Brazil (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Latin America (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Asia-Pacific
Japan (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
South Korea (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
China (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
India (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)Australia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Vietnam (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Malaysia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Indonesia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Philippines (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Thailand (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Asia-Pacific (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Middle East & Africa
Saudi Arabia (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Iran (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Egypt (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Oman (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
South Africa (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Rest of Middle & Africa (Value and Volume, 2012 – 2024)
By Monitoring Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring)
By Management Device (Insulin Pump, Syringes, Cartridges, Disposable Pens, Jet Injectors)
By Company (Roche, Dexcom, Abbott, Novo Nordisk and Others)
Europe Cancer Therapeutics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 70 pages | Published: 17-06-2019 |
- Healthcare
- Mordor Intelligence
- 70 pages
- Published: 17-06-2019
Market Overview
The propelling factors for the growth of the European cancer therapeutics market include the ease in regulatory approval for novel cancer therapy in Europe, increase in healthcare spending for cancer, rising prevalence of cancer, and strong R&D initiatives from key players.
The increasing cancer among the population represents the second most important cause of death and morbidity in Europe, accounting for 1.9 million deaths every year. According to WHO, Europe comprises only one-eighth of the total world population, but has around one-quarter of the total global cancer cases. Around 3.7 million new patients are being reported every year in Europe. There are also other factors attributed to the rising incidence of cancer in Europe, i.e. unhealthy lifestyles and inappropriate diet, obesity, and lack of physical activity. Thus, the growing incidence and prevalence of cancer is likely to drive the growth of the cancer therapeutics market in Europe during the forecast period.
The direct cost of cancer has also increased, and thus the cost of cancer drugs as a share of direct health costs has doubled. The increase in the cost of the cancer treatment, along with the drugs prices, has resulted in the growth of the overall market.
In addition, the heavy investments made in R&D activities have enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence have boosted the market growth.
Scope of the Report
As per the scope of the report, cancer therapeutics are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells.
Key Market Trends
Target Therapy is the Largest Growing Segment under Therapy Type During the Forecast Period
The major factors driving the growth of the target therapy segment is the increase in R&D and the rising prevalence of various types of cancers. Targeted therapy is also gaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells. Thus, owing to the rising approval from regulatory bodies and an increase in the prevalence of all types of cancer, the segment is expected to witness a high growth rate over the forecast period.
Immunotherapies/biologics are also emerging as potential therapies to find a permanent cure for various cancer types among various cancer therapeutics.
Competitive Landscape
There are several big pharmaceutical companies present in the market that have started programs to help patients who are suffering from chronic diseases. Thus, there are many hospitals that are found collaborating with the pharmaceutical companies for the treatment and therapy of cancer. With such collaborations, the pharmaceutical companies are able to engage in larger studies that are aimed to speed up the pace of discovery of cancer therapeutics.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Ease in Regulatory Approval for Novel Cancer Therapy in Europe
4.2.2 Increase in Healthcare Spending for Cancer
4.2.3 Rising Prevalence of Cancer in Europe
4.2.4 Strong R&D Initiatives from Key Players
4.3 Market Restraints
4.3.1 Inequality in Access of Cancer Therapy across Europe
4.3.2 High Cost of Cancer Therapies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.2 Target Therapy
5.1.3 Immunotherapy (Biologic Therapy)
5.1.4 Hormonal Therapy
5.1.5 Other Treatment Types
5.2 By Cancer Type
5.2.1 Blood Cancer
5.2.2 Breast Cancer
5.2.3 Prostate Cancer
5.2.4 Skin Cancer
5.2.5 Respiratory/Lung Cancer
5.2.6 Other Cancer Types
5.3 By End User
5.3.1 Hospitals
5.3.2 Specilty Clinics
5.3.3 Cancer and Radiation Therapy Centers
5.4 Geography
5.4.1 Europe
5.4.1.1 Germany
5.4.1.2 UK
5.4.1.3 France
5.4.1.4 Italy
5.4.1.5 Spain
5.4.1.6 Rest of Europe
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 AstraZeneca PLC
6.1.3 Bayer AG
6.1.4 Bristol-Meyrs Squibb Company
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Merck & Co. Inc.
6.1.9 Novartis AG
6.1.10 Pfizer Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Treatment Type
Chemotherapy
Target Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Other Treatment Types
By Cancer Type
Blood Cancer
Breast Cancer
Prostate Cancer
Skin Cancer
Respiratory/Lung Cancer
Other Cancer Types
By End User
Hospitals
Specilty Clinics
Cancer and Radiation Therapy Centers
Geography
Europe
Germany
UK
France
Italy
Spain
Rest of Europe